Benzeneacetamide, N-9-decenyl-4-hydroxy-3-methoxy- | 107512-61-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: Benzeneacetamide, N-9-decenyl-4-hydroxy-3-methoxy-
• 英文别名: N-dec-9-enyl-2-(4-hydroxy-3-methoxyphenyl)acetamide
• CAS: 107512-61-8
• 化学式: C₁₉H₂₉NO₃
• 分子量: 319.444
• InChiKey: OKVZSDSHRCJXLQ-UHFFFAOYSA-N

物化性质

• 沸点：
  524.6±50.0 °C(Predicted)
• 密度：
  1.027±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  23
• 可旋转键数：
  12
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  高香草酸 在 sodium hydroxide 、 氯化亚砜 、 硫酸 、 三乙胺 作用下， 以 甲醇 、 氯仿 为溶剂， 反应 6.0h， 生成 Benzeneacetamide, N-9-decenyl-4-hydroxy-3-methoxy-
  参考文献：
  名称：

  香草。1.具有抗伤害感受和抗炎活性的辣椒素类似物。

  摘要：

  作为建立香草醛的结构活性关系的程序的一部分，辛辣成分辣椒素的类似物，母体结构的烷基链部分（以及衍生自高香草酸的相关化合物）发生了变化。在抗伤害感受和抗炎试验（大鼠和小鼠热板以及巴豆油刺激的小鼠耳朵）中，具有广泛变化的烷基链结构的化合物具有活性。短链化合物在上述测定中通过全身给药具有活性，但它们保留了辣椒素的高刺激性和急性毒性特征。相比之下，长链顺式不饱和物NE-19550（香草基油酰胺）和NE-28345（油基单香草酰胺）具有口服活性，刺激性较低，并且比辣椒素的急性毒性小。

  DOI：

  10.1021/jm00070a002

文献信息

• Pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
  申请人：Propanc Pty Ltd

  公开号：US10350239B2

  公开（公告）日：2019-07-16

  The present invention generally relates to pharmaceutical compositions containing a protease proenzyme and use thereof for treating cancer. The pharmaceutical compositions are directed to compositions comprising a protease proenzyme and an active agent, the composition being capable of providing a multi-functional approach for treating cancer. The pharmaceutical compositions are also directed to compositions comprising a first and a second protease proenzyme capable of activation at or near a surface of a tumor cell to enhance cell-to-cell adhesion of tumor cells, effect proteolysis of tumor cells, or induce tumor cell apoptosis, differentiation or immunorecognition, wherein the first protease proenzyme is chymotrypsinogen and the second protease proenzyme is trypsinogen. The pharmaceutical compositions are also directed to compositions comprising a first and second active agent each capable of inducing intracellular activity in tumor cells.

  本发明一般涉及含有蛋白酶原的药物组合物及其治疗癌症的用途。这些药物组合物涉及包含蛋白酶原和活性剂的组合物，该组合物能够提供治疗癌症的多功能方法。本发明的药物组合物还涉及包含第一和第二蛋白酶原的组合物，第一和第二蛋白酶原能够在肿瘤细胞表面或其附近活化，以增强肿瘤细胞的细胞间粘附性，影响肿瘤细胞的蛋白分解，或诱导肿瘤细胞凋亡、分化或免疫认知，其中第一蛋白酶原是糜蛋白酶原，第二蛋白酶原是胰蛋白酶原。该药物组合物还涉及包含第一和第二活性剂的组合物，每种活性剂都能诱导肿瘤细胞的细胞内活性。
• COMBINATIONS OF VANILLOID COMPOUNDS AND NUCLEOSIDE ANTIVIRAL COMPOUNDS FOR TREATMENT OF HERPES INFECTIONS
  申请人：THE PROCTER & GAMBLE COMPANY

  公开号：EP0559744A1

  公开（公告）日：1993-09-15
• A PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT
  申请人：Propanc Pty Ltd

  公开号：EP2490711A1

  公开（公告）日：2012-08-29
• PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND CHYMOTRYPSINOGEN
  申请人：Propanc Pty Ltd

  公开号：EP3095458B1

  公开（公告）日：2018-07-25
• PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT
  申请人：Kenyon Julian Norman

  公开号：US20120251516A1

  公开（公告）日：2012-10-04

  The present invention generally relates to pharmaceutical compositions containing a protease proenzyme and use thereof for treating cancer. The pharmaceutical compositions are directed to compositions comprising a protease proenzyme and an active agent, the composition being capable of providing a multi-functional approach for treating cancer. The pharmaceutical compositions are also directed to compositions comprising a first and a second protease proenzyme capable of activation at or near a surface of a tumour cell to enhance cell-to-cell adhesion of tumour cells, effect proteolysis of tumour cells, or induce tumour cell apoptosis, differentiation or immunorecognition, wherein the first protease proenzyme is chymotrypsinogen and the second protease proenzyme is trypsinogen. The pharmaceutical compositions are also directed to compositions comprising a first and second active agent each capable of inducing intracellular activity in tumour cells.